Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: A Randomized Clinical Trial.
JAMA PediatrOct 1, 2026
Robert A Wood, Alkis Togias, Caitlin M Burk et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized clinical trial compared the efficacy of omalizumab versus multiallergen oral immunotherapy (MOIT) in treating multifood allergies in participants aged 1 to 55 years. The study found that omalizumab was superior, with 36% of participants achieving a cumulative tolerated dose (CTD) of 4044 mg or greater compared to 19% for MOIT (P = .03).
Key findings
- Omalizumab showed a treatment success rate of 36% compared to 19% for MOIT (P = .03).
- 51% of participants receiving omalizumab completed the study versus 30 participants (51%) for MOIT.
- Serious adverse events occurred in 31% of MOIT participants compared to 0% in the omalizumab group.
- 37% of MOIT participants required epinephrine treatment compared to 7% in the omalizumab group.
Why it matters
The findings highlight the potential of omalizumab as a more effective treatment option for patients with multifood allergies, particularly given the higher rates of adverse events associated with MOIT.